Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Adalimumab

Central nervous system demyelination

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Shirah B, et al. Adalimumab-induced central nervous system demyelination in a patient with rheumatoid arthritis. Neuroradiology Journal 37 : 234-236, No. 2, Apr 2023. Available from: URL: https://dx.doi.org/10.1177/19714009231173102 Shirah B, et al. Adalimumab-induced central nervous system demyelination in a patient with rheumatoid arthritis. Neuroradiology Journal 37 : 234-236, No. 2, Apr 2023. Available from: URL: https://dx.doi.org/10.1177/19714009231173102
Metadaten
Titel
Adalimumab
Central nervous system demyelination
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55858-3

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Flecainide

Case report

Multiple drugs